T1	Participants 450 669	In this double-blind, parallel-group study, patients naive to emetogenic chemotherapy (N = 1,085) who were scheduled to receive cyclophosphamide- (500 to 1,200 mg/m2) or carboplatin (> or = 300 mg/m2) based chemotherapy
T2	Participants 811 843	patients in each treatment group
T3	Participants 1093 1101	patients
T4	Participants 1573 1628	More patients who received ondonsetron than granisetron
